He has been instrumental in the development of a number of agents that have subsequently been approved for clinical usage such as mitoxantrone in hormone refractory prostate cancer and gemcitabine in both pancreatic and urothelial cancer. Dr Moore has 90 peer reviewed publications and has given over 100 invited lectures.